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ABSTRACT 
 
Metabolic syndrome (MetS) is a group of obesity-related metabolic abnormalities that 
predisposes to type II diabetes mellitus (T2DM) and cardiovascular disease. The dramatic 
increase in incidence of obesity and MetS over the last 25 years amidst relatively constant host 
genetics supports the role for non-genetic factors such as gut microbiota composition as an 
important contributor to the development of these disorders. Microbiota can interact with the 
host, in a manner influenced by genetics and diet that result in low-grade chronic inflammation.  
A critical risk factor for the pathogenesis of obesity and its related MetS involves alteration of gut 
microbiota composition with increased innate immune system activation in the intestine 
increasing risk. Diet-induced obesity is often modeled by comparing mice fed high-fat diet 
(HFD), which is made from purified ingredients, vs. normal chow diet (NCD), which is a low-fat 
assemblage of relatively unrefined plant and animal products. The mechanism by which HFD 
promotes adiposity is complex but thought to involve low-grade inflammation and altered gut 
  microbiota. Here, I investigated the extent to which physiological effects to which HFD-induced 
adiposity is driven by fat content per se vs. other factors that differentiate HFD vs. NCD or other 
compositionally-defined diets (CDD) and, moreover sought to define the mechanisms that drove 
such effects. Relative to NCD, HFD, and to a lesser but nonetheless significant extent, CDD 
induced increased adiposity in addition to a rapid and marked loss of cecal and colonic mass, 
indicating that both lipid content and other aspects of HFD are obesogenic. CDD-induced effects 
were not affected by adjusting dietary protein levels/types but could be largely eliminated by 
exchanging insoluble fiber (cellulose) for soluble fiber (inulin). Moreover, replacing cellulose 
with inulin in HFD protected mice against decreased intestinal mass, hyperphagia and increased 
adiposity. Such protective effects of inulin correlated with increased levels of short-chain fatty 
acids, which are the products of bacterial fermentation of inulin. Lack of a microbiota, achieved 
by use of germ-free mice prevented generation of SCFA and eliminated the beneficial effects of 
inulin. Together, these results indicate that HFD-induced obesity is promoted by its lack of 
soluble fiber, which, when present, supports microbiota-mediated intestinal epithelia homeostasis 
that prevents inflammation driving obesity and MetS. 
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1 Introduction 
 
 
1.1 Metabolic Syndrome 
 
Metabolic syndrome (MetS) is a group of obesity-related metabolic abnormalities that 
increases predisposition to Type II diabetes mellitus (T2DM) and cardiovascular disease.  In 
both adults and children the emerging epidemic of obesity, a hallmark feature of MS that also 
includes hyperlipidemia, hypertension, and insulin resistance (IR), parallels with the dramatic 
increase of T2DM, the seventh leading cause of death in the USA. T2DM affects more than 380 
million people worldwide and is expected to increase by more than 50% by the year 2035. 
Unfortunately, treatments for obesity, through medical intervention and lifestyle changes, have 
failed to achieve long-term success (Chen, Z., et al. 2014). The estimated health care cost of 
obesity and T2DM in 2012 was $190 billion and$245 billion, respectively!  Thus, MS is a 
burgeoning clinical problem plaguing our country’s health and economy and therefore has high 
clinical and economic significance. Alternative and novel strategies are warranted for long-term 
treatment and prevention (Chen, Z., et al. 2014). 
Current approaches to the MetS problem have been largely unsuccessful and primarily 
have focused on dietary excess (diet-induced obesity [DIO]). Rodent model systems have been 
used to examine the effects of microbiome change resulting from various high fat diets (HFDs), 
which emulates the high-fat/high-density foods in modern society contributing to the MetS trend 
in humans. Correlations between obesity, inflammation and IR were found, but the causal role of 
HFD is poorly understood. However, studies showing a reciprocal relationship between metabolic 
disorders and the composition of the gut microbiota suggests that it may be a viable therapeutic 
target, and potentially define how intrinsic and extrinsic factors alter not only its composition and 
function, but also interactions with the host (Chen, Z., et al. 2014). 
 
 
 
 
1.2 Function and Importance of the Gut Microbiota 
 
The gastrointestinal tract (GIT) contains a series of hollow organs that takes on the 
immense task of digestion and absorption of dietary nutrients, along with excretion of waste 
material. The organs of the GIT work in harmony to shuttle nutrients to parts of the body where it 
is needed most for energy use and storage (Shen, 2009). We are now learning that microbial 
inhabitants of the gastrointestinal tract, known as the gut microbiota, is a powerful metabolic 
organ that not only plays a dominant role in the digestive process, but also is a significant aspect 
in many biological processes that include immunity, regulation of metabolic function, vitamin 
production (Vitamins K and B), digestion of complex carbohydrates, production of short chain 
fatty acids, and biotransformation of lipids and conjugated bile acids (Canny & McCormick, 
2008). 
 
Currently, about 12 bacterial phyla and 1,000 species have been classified in the human 
GIT. Dominant bacteria of the GIT belong to the phyla Firmicutes and Bacteroidetes, (Bäckhed 
et al., 2005). Other phyla in lower abundance include Actinobacteria, Proteobacteria, 
Fusobacteria, Lentisphaerae Spriochaetes, Deinococcus-Thermus,Verrucomicrobia and the 
candidate division TM7which is a class of unculturable microorganisms. Common genera of the 
GIT are Bacteroides, Clostridium, Prevotella, Fusobacterium, Enterococcus, Staphylococcus, 
Streptococcus, Eubacterium, Bifidobacterium, Lactobacillus, Peptostreptococcus, Escherichea, 
and Veilionella (Rodriguez et al., 2015; Ley et al., 2006; Dethlefsen et al, 2006) Among the 12 
phyla, the most scrutiny has been placed on Firmicutes, Bacteroidetes, Actinobacteria and 
Proteobacteria due to their dominance and variability amongst the human population. It is a 
challenging effort to describe the complete composition of the human gut microbiota at the 
 
 
 
 
species level due to individual variations in overall microbial composition. However, more than 
 
400 bacterial species have been analyzed within the fecal contents of a single person. 
Dominated by facultative and strict anaerobic bacteria, microbial diversity and abundance 
increases down the length of the GIT from the mouth to the anal canal, with the largest 
population of microbes contained within distal portions of the ileum, and the colon. Microbiota 
of the colon is estimated to contain 10
12 ml per gram of bacteria (O’Hara and Shanahan, 2006) 
that function as either autochtonous or allochthonous flora (Mackie, Sghir, & Gaskins, 1999). 
According to Round et al. (2009), the human gut encompasses various classes of 
microorganisms that include commensals, symbionts and pathobionts. Symbiotic 
microorganisms benefit the host by harmoniously providing nutrients and protection where both 
the host and microorganisms benefit. Commensal microorganisms are considered permanent 
members of the gut that do not benefit or cause harm to the host, however commensals can 
become pathobionts if conditions are favorable. Pathobionts may also live permanently within 
the GIT and are capable of causing disease or infection within the host if conditions are 
favorable where they out number beneficial microorganisms within its environment (Round et 
al., 2009). 
Although most microorganisms are capable of eliciting an immune response due to tissue 
damage and inflammation, there are several species of beneficial gut microbiota that are capable 
of protecting the human host from disease and infection (Musso et al., 2011). Through a process 
called colonization resistance, beneficial bacteria of the gut produce regulatory products such as 
bacteroicins to prevent pathobionts from colonizing the gut. If the delicate balance between 
symbionts and pathobionts is disturbed, it results in a disruption or dysbiosis of the microbial 
population (Kamada et al., 2013). 
 
 
  
The outcome results in systemic inflammation where inflammatory products of Gram- negative 
bacteria such as lipopolysaccharides (LPS) enter circulation (Cani & Iglesias, 2007). This allows 
gut microbiota have the ability to mediate inflammation causing abnormal function of immune 
and metabolic responses (Musso et al., 2011). Bacterially mediated inflammation stemming from 
the gut has been linked with several health disparities such as obesity, irritable bowel disease 
(IBD), Type 2 diabetes, colon cancer and allergies (Teixeira et al., 2012; Musso et al., 2011). 
 
 
1.3 The Effects of Diet Induced Obesity on the Microbiota 
 
Diet plays a pivotal role in causing MetS in humans as modern food production lack 
complex fiber and carbohydrates, but is high in refined sugar. Common mouse models utilize 
diet to induce or exacerbate MetS and compare groups on a normal chow diet (NCD), which is of 
undefined composition, to a purified, compositionally defined diet (CDD) high in fat content. 
CDD is viewed in nutrition literature as an appropriate control diet as it mimics the amount of 
calories, fat, protein and carbohydrates found in traditional mouse chow, but listed ingredients 
show that it differs from chow most notably in its fiber content, replacing the insoluble cellulose 
fiber typically used with the soluble fiber inulin which is known to change intestinal bacteria 
distribution. 
Diet is a powerful element that can drastically compromise the functionality of the GI 
tract and alter the composition of the microbiota. Human and Animal studies provide evidence 
that a major determinant of the health of an individual that is modifiable depending on continual 
dietary consumption, dietary patterns and metabolic status is composition of the gut microbiota 
(Shen et al., 2013).  About 90% of an individual’s microbiota community structure contains a 
common structure that is dominated by members of the phyla Bacteroidetes and Firmicutes based  
 
 
  
on fecal microbial contents. Fluctuations or dysbiosis within the ratio of the two phyla can create 
an inflammatory stimulus from undigested/unabsorbed nutrients that allows members of the 
microbial community to harvest up to 10% of energy from the host diet that contributes to an 
individual’s overall dietary intake, and promotes storage of excess energy within adipose tissue. 
(Backhed et al., 2004; Turnbaugh et al., 2006). 
Individuals who consume a diet rich in plant polysaccharides and fermentable fibers have 
been shown to contain a fecal microbiota rich in Bacteroidetes with lower levels of Firmicutes, 
which represents a lean and healthy phenotype. In comparison, individuals who consume diets 
rich in proteins and animal fats have been shown to harbor a microbial composition that is higher 
in the level of Firmicutes to Bacteroidetes that is associated with an overweight/obese phenotype 
and accumulation of body fat and insulin resistance (DeFilipo et al., 2010). However, the same 
results have not been observed between lean and obese phenotypes leaving identification of a 
lean or obese microbiota under constant debate. (Laugerette et al, 2011; Zhang et al., 2009; 
Duncan et al., 2008). 
A diet high in dietary fats diet or an obesogenic environment has been also shown to 
increase the levels of the phyla Proteobacteria and family Enterobacteriaceae that are composed 
of Gram negative bacteria may contribute to diet induced dysbiosis and cause inflammation (Ley 
et al., 2005; Ley et al., 2006). It is suggested that residual dietary components from a diet that is 
high in dietary energy form either a high fat or high carbohydrate diet increase LPS production 
(Pailey et al, 2015) caused by Gram-negative bacteria. The dissemination of LPS compromise 
the gut epithelial lining and increase intestinal permeability creating “leaky gut” allowing the 
 
 
 
passage of bacteria and their inflammatory products through tight junction transmembrane 
proteins (Bengmark, 2013). Once inflammatory products are released into systemic circulation 
the immune system triggers an inflammatory response increasing the release of pro- 
inflammatory cytokines such IL-6, IL-8 and TNF-α activity (Cani et al., 2007). 
 
 
1.4 Summary 
 
Understanding HFDs and the microbiota as an important facet of the inflammatory 
response is clinically significant.  We previously used this approach to examine how high-fat diet 
(HFD) influences susceptibility to murine colitis and showed that maintaining mice on either 
high-fat (60%) diet or compositionally-defined control (10% fat) diet induce low-grade 
inflammation and dramatically exacerbate dextran sodium sulfate (DSS)-induced colitis. Further 
studies indicated that in the absence of DSS, regardless of fat content, CDD rapidly induced 
alterations in gut morphology, including loss of cecal mass, indicative of gut inflammation, 
ultimately suggesting CDD alone induced inflammation, but the mechanisms underlying this 
inflammatory response is not known. I hypothesize that CDD drives intestinal inflammation by 
an inability to maintain a stable healthy gut microbiota due to lack of soluble fibers, thereby 
altering rates of epithelial apoptosis and proliferation.  
 The goal of this work will seek to identify the mechanisms by CDD that induces 
regulatory and/or effector immune responses through the gut microbiota. The following specific 
aims will test my hypothesis. Specific aim one will identify macronutrients that promote a 
healthy microbiota and protection against gut atrophy.  This aim will be addressed by 1) testing
  
what component of CDD induce low grade inflammation and the development of obesity and 
MetS,  2) identifying the mechanisms involved in protection from low grade inflammation and 
the development of obesity and MetS by CDD and 3) determining the effects of antibiotics and 
if induction of  low grade inflammation require MyD88-mediated pro inflammatory signaling. 
Specific aim two identify the extent to which CDD and fiber supplementation impacts “classic” 
gut inflammation; i.e. colitis. This aim will be addressed by 1) showing that CDD promotes 
colitis in IL-10KO and DSS models and 2) determining if the soluble fiber Inulin can protect 
against colitis in both IL-10KO and DSS models.  Understanding the mechanisms linking CDD 
to alterations in the gut microbiota is necessary for regulation of dysbiosis and ensuring 
promotion of anti-inflammatory effects.  
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2.1 Abstract 
 
Diet-induced obesity is often modeled by comparing mice fed high-fat diet (HFD), which is 
made from purified ingredients, vs. normal chow diet (NCD), which is a low-fat assemblage of 
relatively unrefined plant and animal products. The mechanism by which HFD promotes 
adiposity is complex but thought to involve low-grade inflammation and altered gut microbiota. 
The goal of this study was to investigate the extent to which HFD- induced adiposity is driven 
by fat content vs. other factors that differentiate HFD vs. NCD. Mice were fed NCD, HFD, or 
other compositionally defined diets (CDD), designed to mimic NCD and/or explore the role of 
HFD components. A range of metabolic parameters reflecting low-grade inflammation and 
adiposity were assayed. Rela- tive to NCD, HFD, and to a lesser, but, nonetheless, significant 
extent, CDD induced increased adiposity, indicating both lipid content and other aspects of HFD 
are obesogenic. Moreover, HFD and CDD induced a rapid and marked loss of cecal and colonic 
mass. Such CDD-induced effects were not affected by adjusting dietary protein levels/types but 
could be largely eliminated by exchanging insoluble fiber (cellulose) for soluble fiber (inulin). 
Replacing cellulose with inulin in HFD also protected mice against decreased intestinal mass, 
hyperphagia, and increased adiposity. Such beneficial effects of inulin were microbiota 
dependent, correlated with elevated fecal short-chain fatty acid levels analyzed via 1H-NMR-
based metabolomics and were partially recapitulated by administration of short-chain fatty acid. 
HFD-induced obesity is strongly promoted by its lack of soluble fiber, which supports 
microbiota-mediated intestinal tissue homeostasis that prevents inflammation driving obesity 
and metabolic syndrome. 
 
 
 
 
  
 
2.2 Introduction 
 
The dramatic increased incidence of obesity, and its interrelated disorders, underscores the 
importance of understanding the pathophysiology of this disorder. While broad societal changes 
in diet are almost certainly central to the obesity epidemic, mechanisms by which changes in diet 
eventuate in obesity are complex. A commonly used means to model diet-induced obesity (DIO) in 
rodents is to administer an energy dense high-fat diet (HFD). While consumption of HFD likely 
results directly in extra calories that are efficiently converted to fat, the mechanisms that perpetuate 
and sustain continued excess caloric consumption are increasingly viewed to involve low-grade 
inflammation driven, in part, by gut microbiota (17). Specifically, HFD induces alteration of gut 
barrier function that results in translocation of lipopolysaccharide across the intestine (5, 19). Such 
lipopolysaccharide may drive low-grade proinflammatory gene expression that can desensitize 
signaling by insulin (i.e., insulin resistance) and other satiety signaling pathways. In support of this 
notion, DIO can be ameliorated in germ-free mice, by antibiotic treatment, or by absence of Toll-
like receptor (TLR)-4 (3, 6, 22). 
 Most published studies, including ours (11, 23), that utilize HFD model of DIO examine 
differences between animals fed “rodent chow” to those fed HFD. However, these diets differ in a 
number of ways other than their fat content. Chow (e.g., LabDiet5001) is assembled from a broad 
array of partially processed and relatively unrefined plant and animal products. The components of 
chow are not well characterized and likely exhibit batch (lot), seasonal, and vendor-to-vendor 
variability. In contrast, HFD is a compositionally defined diet (CDD) manufactured from purified 
ingredients, each containing one main nutrient. Thus, as has been noted in the nutrition literature,  
 
 
 
 
  
studies seeking to define the role of HFD components in DIO ought to compare HFD to CDD that 
differ only in a limited number of specific components, especially percent fat content. Indeed, 
herein we report that two different commercial CDD, designed to match chow nutritionally and to 
be control diets for HFD, drove decreased intestinal mass and increased adiposity relative to mice 
fed chow. Investigation of the underlying mechanisms revealed that, in contrast to chow, HFD and 
control CDD failed to support intestinal health, correlating with their lack of soluble fiber. Addition 
of soluble fiber to CDD restored intestinal health and protected against HFD-induced adiposity.  
 Such beneficial effects of inulin were dependent on the presence of a microbiota and 
correlated with increased production of short-chain fatty acids (SCFA). Thus we report that use of 
CDD ought to contain soluble fiber to maintain a healthy intestine, and that supplementation of 
various diets might further promote intestinal health that can protect against low-grade 
inflammation that drives adiposity. 
 
 
 
2.3 Materials and Methods 
 
 
2.3.1 Mice 
 
Wild-type C57BL/6 mice were purchased from Jackson Laboratories. All mice were then 
housed at Georgia State University (Atlanta, GA) under institutionally approved protocols 
(Institutional Animal Care and Use Committee no. A14033). Mice were fed Purina rodent chow 
(cat. no. 5001) from LabDiets, unless another diet is specified  
 
 
 
 
 
 
  
 
2.3.2 Diets 
 
Diets were procured from Research Diets (New Brunswick, NJ) or Harlan (Indianapolis, 
IN). The composition of all diets used in this study was detailed in Tables 1 and 2. Fiber was 
added on a similar per kilocalorie basis in low- and high-fat diet formulas, and inulin was 
considered as 1.0 kcal/g, replacing an equal amount of kilocalories from starch (or maltodextrin 
in formulas with 60 kcal% fat). We considered cellulose to provide no calories. 
 
2.3.3 Mice Treatment 
 
Mice were fed with “normal” chow diet (NCD) of specified CDD for a period of 2 days 
to 12 wk. NCDs were autoclaved for experiments using germ-free mice. Body weights were 
measured every week and are expressed as a percentage gain compared with the initial body 
weight (day 0), defined as 100%. At the end of diet treatment, mice were fasted for 5 h. Mice 
were then euthanized, and colon length, colon weight, spleen weight, and adipose weight were 
measured. Organs were collected for downstream analysis. 
 
 
2.3.4 Food Intake Measurement 
 
Groups of mice were placed in a clean cage with a known amount of food. Twenty-four 
hours later, the amount of remaining food was measured with the difference viewed as food intake 
per 24 h. 
 
 
 
 
 
 
  
 
2.3.5 Antibiotic Treatment 
 
Mice were placed on broad-spectrum antibiotics ampicillin (1.0 g/l) and neomycin (0.5 g/l) 
in drinking water for 4 wk (23). As ampicillin and neomycin are poorly absorbed, such treatment 
primarily affects only intestinal microbiota without direct systemic effects (15). 
 
2.3.6 SCFA Treatment 
 
Mice were put on drinking water supplemented with a mixture of SCFA (67.5 mM 
sodium acetate, 40 mM sodium butyrate, and 25.9 mM sodium propionate) for 21 days (21). 
 
2.3.7 Germ-Free Experiments 
 
Germ-free C57BL/6 mice were kept under germ-free conditions in a Park Bioservices 
isolator in our germ-free mice facility. After 4 wk of diet feeding, mice were fasted for 5h and 
then removed from the isolator to be euthanized immediately. Samples were collected as 
previously described. 
 
 
2.3.8 NMR Spectroscopy 
 
All 1H NMR spectra of fecal extracts were recorded at 298 K using a Bruker Avance III 
600 MHz NMR spectrometer (operating at 600.08 MHz for proton, Bruker Biospin), equipped 
with an inverse cryogenic probe. A one-dimensional NMR spectrum was acquired for each of  
 
 
 
 
 
 
  
all samples, employing the first increment of NOESY pulse sequence (recycle delay-90°-t1-
90°-tm-90°-acquisition) with a spoil gradient for water presaturation. The recycle delay of 2 s, 
t1 of 4 μs, and the mixing time (tm) of 100 ms were set. The 90° pulse length was adjusted to 10 
μs. A total of 64 scans were collected into 32k data points for each spectrum with a spectral 
width of 20 ppm. For resonance assignment purposes, a series of two-dimensional NMR 
experiments (1H−1H correlation spectroscopy, 1H−1H total correlation spectroscopy, 1H−13C 
heteronuclear single quantum correlation spectroscopy, and 1H−13C heteronuclear multiple 
bond correlation spectroscopy) were carried out on the selected samples. 
 
2.3.9 Spectral Data Processing and Multivariate Data Analysis 
 
All  1H NMR spectra were corrected manually for phase and baseline distortions, and 
spectral region δ 0.5–9.5 was integrated into regions with equal width of 0.004 ppm (2.4 Hz) 
using AMIX software package (V3.8, Bruker-Biospin). Regions distorted were discarded. These 
regions are δ 4.45–5.20 for imperfect water saturation in both cecal and fecal extracts, and δ 
1.15–1.23 and δ 3.62–3.69 for ethanol contaminations during the mouse dissection process. Each 
bucketed region was then normalized to the total sum of the spectral integrals to compensate for 
the overall concentration differences before statistical data analysis. Multivariate data analysis 
was carried out with the SIMCAP+ software (version 13.0, Umetrics, Sweden). Principal 
component analysis was initially carried out on NMR data to generate an overview. Orthogonal 
projection to latent structure with discriminant analysis (OPLS-DA) was  
 
 
 
 
 
 
  
subsequently conducted using NMR data. The OPLS-DA models were validated using a 
sevenfold cross-validation method, and the quality of the model was described by the parameters 
R2X and Q2 values. To facilitate interpretation of the results, back-transformation (13) of the 
loadings generated from the OPLS-DA was performed before generating the loadings plots, 
which were color-coded with the Pearson linear correlation coefficients of variables (or 
metabolites) using an in-house developed script for MATLAB (The Mathworks, Natwick, MA). 
The color-coded correlation coefficient indicates the significance of the metabolite contribution 
to the class separation, with a “hot” color (e.g., red) being more significant than a “cold” color 
(e.g., blue). In this study, a cutoff value of |r| > 0.707 (r > 0.707 and r < −0.707) was chosen for 
correlation coefficient as significant based on the discrimination significance (P ≤ 0.05). 
 
2.3.10 Statistical Analysis 
 
Significance was determined using one-way ANOVA corrected for multiple comparisons 
with a Bonferroni test (GraphPadPrism software, version 6.01). Differences were noted as 
significant at P ≤ 0.05. 
 
 
2.4 Results 
 
 
2.4.1 CDD are obesogenic and induce loss of intestinal mass. 
 
 
C57Bl/6 mice, in all cases herein fed ad libitum, were maintained on a NCD through the 
post weaning period (i.e., until 6 wk of age) so as to allow their mucosal immune system to 
mature and gut microbiota composition to stabilize (10, 14). Mice were then switched to one of  
 
 
 
  
 
two CDD, which are assembled from purified quality-controlled ingredients. One CDD 
contained 60% fat, i.e., HFD (HFD or CDD-60%), and has been widely utilized in research to 
promote obesity, while the other CDD contained 10% fat (CDD-10%) and can be viewed as an 
appropriate control diet for the HFD in that it is made from the same ingredients, albeit in 
different proportions and, moreover, is thought to be similar to chow in terms of its basic 
nutrient/calorie content. Relative to NCD-fed mice, mice fed HFD exhibited marked weight 
gain (Fig. 1A) that corresponded with development of epididymal fat pads about fourfold larger 
than that of NCD-fed animals (Fig. 1B). An intermediate result was observed with mice fed a 
CDD composed of 10% fat (CDD-10%). (Fig. 1, A and B). This pattern of results was 
consistently seen in multiple experiments and when both CDD were purchased from different 
vendor (data not shown). These results confirm that fat content is a key driver of the DIO  
phenotype, but also indicate that other differences between HFD and NCD contribute to HFD's 
promotion of obesity. Obesity is associated with, and promoted by, low-grade chronic 
inflammation. A correlate of low-grade intestinal inflammation is shortening of the colon, which 
is often accompanied by loss of cecal and colonic mass (24). Indeed, a striking consequence of 
feeding mice either HFD or control CDD was a dramatic loss of cecal and colonic tissue mass. 
Specifically, relative to chow-fed mice, the intestine of CDD-fed mice appeared thin and 
atrophied (Fig. 1C), which correlated with a shortening of the colon and loss of cecal and  
 
 
 
 
 
 
  
 
colonic mass that could be quantitated by weighing cecum (with contents) and colon (without 
contents) (Fig. 1, D and E). We reasoned that such gross effects on the intestine by CDD might 
be pivotal to their promotion of adiposity and, hence, sought to understand their cause. 
 
 
2.4.2 CDD-induced changes are rapid and involve gut bacteria. 
 
HFD-induced obesity is thought to involve interactions between the gut microbiota and 
host innate immune system that promotes low-grade inflammation. Consequently, the extent to 
which obesity is induced by HFD is reduced by antibiotic treatment (6). Analogously, the 
adiposity induced by low fat (10%) CDD-10% was significantly reduced by antibiotic treatment 
(Fig. 2A). Moreover, such amelioration of CDD-induced adiposity by antibiotic treatment was 
accompanied by a partial restoration of cecal and colonic tissue (Fig. 2, B–D). We hypothesized 
that these results might reflect that the CDD were increasing bacterial activation of MyD88 
signaling, which is known to mediate a considerable portion of TLR signaling. However, the 
effects of CDD were only modestly reduced in MyD88-deficient mice, suggesting this pathway 
did not play a major role in mediating CDD's effect on the intestine and adipose tissue (Fig. 3). 
Next, we determined the time course with which CDD results in loss of intestinal mass. We 
observed that 2 days of feeding of CDD was sufficient to result in a dramatic loss of cecal mass 
(Fig. 2H) and a significant loss of colon mass/length, which continued to decline over the next 
several days (Fig. 2, F and G) and by 10 days was similar in magnitude to that seen in  
 
 
 
 
 
  
experiments where the diet was maintained for several weeks. A significant increase in adiposity 
was also observed over this relatively short time course (Fig. 2E). Together, these results suggest 
that CDD may alter gross intestinal morphology in a rapid manner that promotes microbiota-
dependent, low-grade inflammation that promotes adiposity. 
 
 
 
2.4.3 Dietary Fiber Content, But Not Protein, Alters Gut Morphology Alterations Induced By 
 
CDD. 
 
In light of our hypothesis that low-grade inflammation plays a key role in DIO, and that a 
healthy gut is necessary to protect the host against inflammation, we sought to better understand 
why CDD might result in loss of intestinal mass. First, to get a better sense of the extent to which 
this phenotype was driven by absence of a gut-maintaining component of NCD or presence of a 
gut-destroying component of CDD, we mixed the diets at a range of ratios of dietary protein or 
fibers. The loss of intestinal mass phenotype was proportional to the percentage of the diet 
composed of CDD, a result consistent with the possibility that the phenotype resulted from loss 
of a nutrient that was limiting in chow, or that it was a dose-dependent consequence of a 
component of CDD (Fig. 4, A–C). We first considered the possibility that the protein component 
of the CDD, namely purified animal protein casein, might be playing a role in the CDD-induced 
phenotype. Hence, we formulated diets in which the purified protein in CDD, casein, was 
replaced with plant-derived soy protein (plant protein source in NCD). This change did not 
significantly impact the CDD-induced loss of intestinal mass or its associated metabolic 
phenotypes (Fig. 4, D–F). Nor did addition of casein or soy to NCD alter these parameters 
relative to a NCD alone, thus arguing against a role for protein type and content (data not shown).  
 
 
 
  
 
Next, we considered the role of the fiber, which is present in NCD, albeit not in a defined 
amount. HFD, and therefore its matched low-fat control CDD, contain the insoluble fiber 
(resistant to bacterial fermentation) cellulose as a sole source of fiber. Exchanging cellulose for 
the soluble fiber (readily undergo bacterial fermentation) inulin largely reversed the deleterious 
effects of the CDD on the intestine (Fig. 5, F–I). This was true, regardless of whether the CDD 
had a protein source of casein or soy protein. Furthermore, mixing cellulose and a CDD 
containing both inulin and cellulose did not result in loss of gut mass, suggesting this phenotype 
may result from CDD's detriment of soluble fiber rather than the presence of cellulose per se. 
Next, we administered diets designed to investigate whether cellulose might have detrimental 
effects or if these results reflected that inulin was promoting gut health, as previously suggested 
(1, 7, 18). In support of this notion, addition of cellulose to chow resulted in only very modest 
loss of gut mass and did so only at relatively high concentrations (4× the fiber typically in CDD) 
(Fig. 5, A and B). Rather, in CDD, levels of inulin correlated well with maintenance of gut mass 
(Fig. 5, C–E), could correct loss of gut mass induced by CDD-10% or CDD-60% (Fig. 5, G–J), 
and addition of inulin to NCD boosted the level of intestinal mass relative to NCD alone (Fig. 5, 
A and B). The restoration of gut mass achieved by exchange of cellulose for inulin correlated with 
amelioration in body weight gain and adiposity induced by HFD (Fig. 6D). We hypothesized that  
the inulin's reduction in HFD would correlate with lower food consumption. However, the 
physical nature of the HFD makes this measure very difficult, as the diet crumbles and cannot be 
easily separated from cage bedding (we sought to avoid use of metabolic cages, which can be  
 
 
 
 
  
 
very stressful to mice and might impact feeding behavior). Hence, we designed a CDD with 45% 
fat (CDD-45%), which does not preclude food consumption measurements and contained 
cellulose or inulin as a fiber source. Analogous to the other CDD, inulin preserved gut mass and 
reduced adiposity relative to mice fed CDD-45% that contained cellulose (Fig. 6, A–D). 
Moreover, such reduction in adiposity in mice fed inulin CDD-45% correlated with reduced food 
consumption (Fig. 6E). Together, these results suggest that soluble fiber may be a limiting 
nutrient in NCD and that its complete absence in CDD contributes to DIO. Moreover, soluble 
fiber may be a means of maintaining gut health and preventing diseases driven by low-grade 
inflammation. 
 
 
2.4.4 SCFA Involvement In Soluble Fiber Protection Of Gut Morphology Alterations 
 
 
We next sought to better understand the mechanism by which inulin promotes gut health. 
First, we used a germ-free approach to investigate microbiota involvement. However, unlike 
chow, CDD cannot be autoclaved, and efforts to sterilize CDD by irradiation at typical doses 
(10–20 kGy) were not successfully achieved (i.e., germ-free mice fed an irradiated CDD 
developed high level of cultivable fecal bacteria; data not shown). Hence, we administered 
sterilized (i.e., autoclaved) inulin-supplemented NCD to conventional and germ-free mice and 
investigated if lack of a microbiota prevented inulin's ability to boost gut mass. We observed 
that inulin's ability to promote colon and cecum mass was completely absent in germ-free mice,  
 
 
 
 
  
indicating its promotion of gut health is likely microbiota dependent (Fig. 7). Microbiota-
mediated production of SCFA is thought to be an important energy source for gut epithelia and 
which bacteria can readily generate from soluble but not insoluble fiber. Hence, we next 
measured levels of fecal SCFA via NMR, and we observed that, relative to NCD-fed mice, mice 
fed CDD, both CDD-10% and HFD-60%, exhibited reduced levels of butyrate, acetate, and 
propionate (Fig. 8, A, B, E). Exchanging the cellulose in these diets for inulin boosted SCFA 
levels (Fig. 8, C–E), supporting the notion that inulin promotes gut health via microbiota-
mediated production of SCFA that protect against inflammation. To further examine this 
possibility, we administered SCFA to the drinking water of CDD-fed mice. Such SCFA 
treatment did not recapitulate all of inulin's beneficial effect, but attenuated CDD-induced 
colonic shortening, indicating partial protection against CDD-induced low-grade inflammation 
(Fig. 9). Together, these results indicate lack of microbiota-produced soluble fiber metabolites is 
pivotal to the maintenance of a healthy mouse intestine and suggest that SCFA production is one 
specific class of metabolites involved in this process. 
 
2.5 Discussion 
 
Societal changes in food production and diet are presumed to be major contributors to the 
epidemic of obesity and its associated diseases. In particular, the increased availability and 
consumption of foods rich in fat and calories is thought to be a major factor underlying the epidemic of 
obesity and its related diseases; i.e., metabolic syndrome. In support of this notion, ad libitum feeding 
of a HFD to mice rapidly increases and recapitulates and/or promotes many features of metabolic  
 
 
 
 
  
syndrome. Consequently, administration of HFD has been widely used to investigate the 
pathophysiology and potential treatments of metabolic syndrome. Such studies indicate that HFD-
induced metabolic disease may be driven, in part, by altered host-microbiota interactions that drive 
low-grade inflammation (8). Yet, how the HFD alters such events remains largely unknown. Even the 
relative role of the HFD's fat content vs. the numerous other ways by which this diet differs from the 
NCD to which it is typically experimentally compared have not been well defined. Herein, we 
observed that, while fat content is an important determinant of the extent to which HFD promotes 
adiposity, other determinants of this diet are pivotal in driving low-grade inflammation and, 
consequently, likely contribute to the HFD-induced phenotype. Specifically, we observed that, among 
mice fed NCD vs. a range of CDD, lack of soluble fiber correlated with cecal and colonic atrophy that 
resulted in microbiota-dependent promotion of adiposity. The notion of diet-induced, microbiota-
dependent increase in adiposity is in accord with the more general hypothesis that a broad range of 
genetic and nongenetic factors that result in disturbance of the microbiota can promote metabolic 
disease (9–11). Consequently, that addition of exogenous soluble fiber (i.e., inulin) protected against 
both gut atrophy and HFD-induced adiposity suggests that increasing dietary soluble fiber intake may 
have broad applicability in ameliorating metabolic disease. 
Dietary fiber intake, which has long been appreciated as an effective means to treat and prevent 
constipation, is increasingly recognized for its association with metabolic health. Consequently, US 
Department of Agriculture dietary guidelines encourage consumption of foods rich in fibers, but do not 
distinguish between soluble and insoluble fibers. Yet our results herein that a soluble fiber, namely  
 
 
 
 
 
  
inulin, but not an insoluble one, namely cellulose, promoted bowel mass and attenuated the obesogenic 
effects of a HFD suggest a major distinction in the ability of such fibers to promote health. The ability 
of inulin to suppress adiposity by CDD diets high in fat content correlated with reduced food intake, 
which seems highly likely to have been a factor in reducing adiposity. That such ability was observed 
relative to CDD containing cellulose argues against the notion that such actions reflect simple addition 
of dietary bulk, but, rather, suggest a key difference in how such fibers are metabolized. Gut 
microbiota readily metabolize soluble fiber into SCFA, notably butyrate, which is known to serve as a 
major fuel source for colonic epithelia and have an array of anti-inflammatory properties, including 
promotion of regulatory T cells (2, 16, 20). Accordingly, we and others have observed near complete 
absence of SCFAs in germ-free mice and, herein, observed that the ability of inulin to increase gut 
mass was absolutely dependent on the presence of a gut microbiota, suggesting that SCFA production 
might contribute to inulin's beneficial effects observed in our model. SCFA-mediated nourishment of 
the epithelium can be envisaged to result in enhanced barrier function that might reduce exposure of 
immune cells to bacterial products that would drive inflammatory gene expression and, consequently, 
phenotypes associated with gut inflammation. However, that addition of SCFA, following a regimen 
reported by others to support gut regulatory T-cell homeostasis (2, 16, 20), only partially recapitulated 
the gut protective effects exhibited by inulin, suggesting that SCFA production may be but one 
mechanism by microbiota metabolism of inulin protection against gut atrophy (21). 
A pivotal observation that drove this study is that, relative to NCD, the ill-defined 
conglomerate of food scraps (grains and animal by-products) that most rodents in biomedical research 
are fed, CDD (with cellulose) assembled from characterized ingredients results in rapid gut atrophy,  
 
 
 
 
  
 
which seems likely to play a role in the obesogenic potential of such diets. Specifically, considering 
that intestinal cell proliferation protects the gut from a range of inflammatory challenges and HFD-
induced obesity involves gut barrier dysfunction and subsequent microbiota activation of 
proinflammatory gene expression, we envisage that such gut atrophy results in increased bacterial 
induction of low-grade inflammation that can promote adiposity (10, 23). That some indexes of CDD-
induced low-grade inflammation, particularly colon shortening, were ameliorated in MyD88-deficient 
mice suggests a role for TLR-mediated detection of bacterial products in driving such low-grade 
inflammation, which is in accord with work of Cani and colleagues that TLR-4 drives HFD-induced 
metabolic syndrome (5). Yet, that such amelioration was only partial indicates that other pathways are 
also likely involved. Given that a large portion of gene expression induced by TLR agonists is in fact 
MyD88-independent (4), additional work will be needed to define other signaling pathways that 
contribute to CDD-induced phenotypes. Moreover, the state of low-grade inflammation induced by 
CDD is not itself well defined, in that CDD induced only very modest increases in myeloperoxidase 
and, moreover, did not associate with clear increases in fecal lipocalin-2, which we have found can 
reliably mark low-grade inflammation in chow-fed mice (12). We hypothesize that this reflects that 
fecal lipocalin-2 is largely produced by epithelial cells, thus obviating its utility as a marker in states 
wherein inflammation may have resulted from gut atrophy. Hence, in future work, it will be important 
to better define the low-grade inflammatory state that results from CDD feeding and to determine how 
this state influences, and is influenced by, gut microbiota. 
In any case, that such phenotypes could be largely prevented by addition of inulin suggests the 
CDD induces gut atrophy as a result of its lack of soluble fiber. However, it is important to note that, at  
 
 
 
  
present, we cannot rule out the possibility that the CDD causes gut atrophy by another mechanism and 
that inulin simply protects against this phenotype by a mechanism not related to its underlying cause 
(Fig. 10). Regardless, the ability of inulin to promote gut mass when added to a wide variety of diets 
may make it an important ingredient in biomedical research. Specifically, the ill-defined nature of 
NCD, its consequent, inherent variability (vendors and different facilities/countries), and, perhaps most 
importantly, the inability to precisely manipulate its components greatly hinder its utility in a broad 
range of experimental approaches, especially those related to macro/micronutrient metabolism and 
host metabolic phenotype. Yet the dramatic deleterious effects of commonly used CDD on gut health, 
irrespective of fat content, suggest that such diets are not a good alternative to NCD. In contrast, as 
shown herein, CDD containing inulin remedy this concern and may serve as a good choice of control 
diet that would be a better mimic of NCD but yet retain tractability. 
In conclusion, supplementation of a broad range of mouse diets with inulin promotes gut mass 
and protects against DIO by a microbiota-dependent mechanism, albeit one whose understanding is far 
from complete. If our observations were to prove applicable to humans, it would suggest encouraging 
consumption of foods with high soluble fiber content may be a means to combat the epidemic of 
metabolic disease. Moreover, addition of inulin, and perhaps other soluble fibers to processed foods, 
including calorically-rich obesogenic foods, may be a means to ameliorate their detrimental effects.
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Figure 2.1 Compositionally defined diets (CDD) are obesogenic and induce loss of intestinal mass. C57Bl/6 mice were 
maintained on the “normal” chow diet (NCD), or, at 4–5 wk of age, switched to the specified CDD for 12 wk (with 10 or 60% 
fat). A: body weight (BW) over time. B: epididymal fat pad weight. C: gross pictures of gut morphology. D: colon weight. E: 
cecum weight. Values are means ± SE of N = 6 mice per group. Significance was determined by Student's t-test. *P < 0.05. 
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Figure 2.2 Microbiota involvement in protection of weight gain and intestinal mass loss induced by CDD. A–D: C57Bl/6 mice were 
maintained on the NCD, or, at 4–5 wk of age, switched to the specified diet and treated with ampicillin (1.0 g/l) and neomycin (0.5 
g/l) in drinking water for 4 wk. A: epididymal fat pad weight. B: colon weight. C: colon length. D: cecum weight. E–H: C57Bl/6 
mice were maintained on the NCD, or, at 4–5 wk of age, switched to the specified diet for 2–10 days. E: epididymal fat pad weight. 
F: colon weight. G: colon length. H: cecum weight. Values are means ± SE of N = 5 (A–D) or 3 (E–H) mice per group. Significance 
was determined by Student t-test. *P < 0.05. ABx, antibiotics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Myd88 involvement in weight gain and intestinal mass loss induced by CDD. C57Bl/6 WT or 
Myd88 knockout (KO) mice were maintained on the NCD, or, at 4–5 wk of age, switched to the specified diet 
for 12 wk. A: epididymal fat pad weight. B: colon weight. C: colon length. D: cecum weight. Values are means 
± SE of N = 5 mice per group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Fiber content, but not protein (Prot) content, alters gut morphology induced by CDD. C57Bl/6 mice were 
maintained on the NCD, or, at 4–5 wk of age, switched to the specified diet for 4 wk. A–C, percentage of diet composed of 
chow and CDD is shown. D–F: Prot and fiber components of the CDD are shown. A and D: colon weight. B and E: colon 
length. C and F: cecum weight. Cell, cellulose; Inul, inulin; Cas, casein. Values are means ± SE of N = 3 mice per group. 
Significance was determined by Student t-test. *P < 0.05. 
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Figure 2.5 Soluble fiber-supplemented CDD protect from gut morphology alterations. C57Bl/6 mice were maintained 
on the NCD, or, at 4–5 wk of age, switched to the specified diet for 4 wk. A and B: chow plus Cell or Inul. C–E: CDD 
plus Cell or Inul. F–I: chow and CDD with 10% and 60% fat plus Cell or Inul. A, C, and F: colon length. B, E, and H: 
cecum weight. C and F: colon length. D and G: colon weight. I: BW. J: gross pictures of gut morphology. Values are 
means ± SE of N = 4 (A and B) or 5 (C–J) mice per group. Significance was determined by Student t-test. *P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Soluble fiber-supplemented CDD protect from gut morphology alterations. C57Bl/6 mice were  
maintained on the NCD, or, at 4–5 wk of age, switched to the specified diet for 6 wk. A: colon length. B: colon 
weight. C: cecum weight. D: epididymal fat pad weight. E: food intake. Values are means ± SE of N = 5 mice per 
group. Significance was determined by Student t-test. *P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Figure 2.7 Microbiota involvement in soluble fiber protection of gut morphology alterations. Conventional and germ-free 
C57Bl/6 mice were maintained on autoclaved NCD, or, at 4–5 wk of age, switched to the specified autoclaved diet for 4 wk. A: 
colon length. B: cecum weight. Values are means ± SE of N = 3–5 mice per group. Significance was determined by Student t-test. 
*P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 NMR-based metabolomics reveal short-chain fatty acid (SCFA) involvement in soluble fiber-induced protection of 
gut morphology alterations. A–D: orthogonal projection to latent structure with discriminant analysis score plot (left) and 
correlation coefficient loading plot (right) showing the discrimination between 1H NMR spectra of fecal contents from mice 
fed with the indicated diet for 4 wk. A: NCD vs. CDD-10%. B: NCD vs. CDD-60%. C: CDD-10% vs. CDD-10% + 200 g Inul. 
D: CDD-60% vs. CDD-60% + 200 g Inul. E: relative content of n-butyrate, propionate, and acetate in mice fed with the 
indicated diet for 4 wk. Values are means ± SE of N = 5 mice per group. Significance was determined by Student t-test. *P < 
0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 SCFA involvement in soluble fiber protection of gut morphology alterations. C57Bl/6 mice were maintained on 
the NCD, or, at 4–5 wk of age, switched to the specified diet and treated with SCFA mix (67.5 mM sodium acetate, 40 mM 
sodium butyrate, and 25.9 mM sodium propionate) in drinking water for 3 wk. A: epididymal fat pad weight. B: colon weight. 
C: colon length. D: cecum weight. Values are means ± SE of N = 5 mice per group. Significance was determined by Student 
t-test. *P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Figure 2.10 Proposed mechanism. 
 
       
 
 
 
      
 
         
 
       Table 1: Purified diets used in the study. 
 
Product # D12450B D12492 D13081101 D13081104 D11112212 D11112213 D11112208 D11112209 D11112210 D11112211 D13081102 D13081103 D14061501 D14061502 
Protein source Casein Casein Casein Casein Soy Soy Casein Soy Casein Casein Casein Casein Casein Casein 
Fiber source Cellulose Cellulose Inulin Inulin Cellulose Inulin Mixed Mixed Cellulose Inulin Inulin Inulin Cellulose Inulin 
kcal% fat 10 60 10 60 15 15 15 15 15 15 10 10 45 45 
               Protein (kcal%) 20 20 20 20 20 20 20 20 20 20 20 20 20 20 
Carbohydrate (kcal%) 70 20 69 19 65 60 62 62 65 60 68 65 35 33 
Fat (kcal%) 10 60 10 60 15 15 15 15 15 15 10 10 45 45 
Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
kcal/gm 3.8 5.2 3.9 5.3 3.5 3.6 3.5 3.5 3.5 3.6 3.8 3.5 4.5 4.6 
               Ingredient (g) kcal/gm               
Casein 4 200 200 200 200 0 0 200 0 200 200 200 200 200 200 
Soy protein 4 0 0 0 0 200 200 0 200 0 0 0 0 0 0 
DL-Methionine 4 0 0 0 0 3 3 0 3 0 0 0 0 0 0 
L-Cystine 4 3 3 3 3 0 0 3 0 3 3 3 3 3 3 
                Corn Starch 4 315 0 302.5 0 387 337 362 362 387 337 290 265 72.8 72.8 
Maltodextrin 10 4 35 125 35 112.5 110 110 110 110 110 110 35 35 100 75 
Sucrose 4 350 68.8 350 68.8 150 150 150 150 150 150 350 350 172.8 172.8 
                Cellulose 0 50 50 0 0 200 0 100 100 200 0 0 0 100 0 
Inulin 1 0 0 50 50 0 200 100 100 0 200 100 200 0 100 
                Soybean Oil 9 25 25 25 25 70 70 70 70 70 70 25 25 25 25 
Lard 9 20 245 20 245 0 0 0 0 0 0 20 20 177.5 177.5 
                RDI Mineral Mix 0 45 45 45 45 45 45 45 45 45 45 45 45 45 45 
                Vitamin Mix, V10001 4 10 10 10 10 10 10 10 10 10 10 10 10 10 10 
Choline Bitartrate 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
                Total gm  1055.05 773.8 1042.5 761.30 1177.00 1127.00 1152.00 1152.00 1177.00 1127.00 1080.00 1155.00 908.10 883.10 
Total kcals  4057 4057 4057 4057 4070 4070 4070 4070 4070 4070 4057 4057 4057 4057 
  
 
 
 
 
 
 
      Table 2. Chow-based diets used in the study 
 
 
Product # C11000 C13062905 C13062906 C13062903 C13062904 C13887 C13889 
Protein source Multiple Multiple Multiple Multiple Multiple Multiple+ Added Casein Multiple+ Added Soy 
Fiber source Multiple Multiple+ Added Cellulose Multiple+ Added Cellulose Multiple+ Added Inulin Multiple+ Added Inulin Multiple Multiple 
        
Ingredient (g)        
Purina 5001 1000 900 800 900 800 850 850 
        
Casein 0 0 0 0 0 150 0 
Soy Protein 0 0 0 0 0 0 150 
        
Cellulose 0 100 200 0 0 0 0 
Inulin 0 0 0 100 200 0 0 
        
FD&C Red Dye #40 0 0.15 0.075 0 0 0 0 
FD&C Blue Dye #1 0 0 0 0.15 0.075 0 0 
        
Total 1000 1000.15 1000.075 1000.15 1000.075 1000 1000 
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3.1 Abstract 
 
The emerging epidemic of metabolic syndrome, a cluster of metabolic diseases that greatly 
increases one’s risk of diabetes, cardiovascular disease, and liver dysfunction has warranted 
understanding in the pathogenesis of such disorders.  Prebiotic strategies have been 
extensively investigated and are thought to be beneficial to intestinal health, however, they 
remain understudied the context of experimental intestinal inflammation.  Here, we 
investigated the pathophysiological effect of compositionally defined diet (CDD) 
supplemented with soluble fiber inulin (prebiotic) in a murine model of DSS-induced acute 
colitis.Wild type C57Bl/6 mice were fed normal chow diet (NCD) or CDD supplemented 
with inulin before and during induction of colitis by adding Dextran Sodium Sulfate (DSS) to 
the drinking water for 7 days. After treatment of 2.5% DSS in drinking water, mice on 
supplemented CDD exacerbates acute colitis which include weight loss, decreased ceacum 
weight, enlarged spleens, bloody stools, and epithelial damage in the colon when compared to 
mice on a NCD.  Regardless of fat content, CDD exacerbate DSS-induced colitis and 
supplementation with inulin results in severe bleeding, weight loss and dramatic loss of colon 
pathology when challenged with DSS. 
 
 
3.2 Introduction 
 
 
 
 Metabolic syndrome is a common and complex disorder whose incidence has 
dramatically increased around the world.  There are many factors which contribute to the 
development of metabolic syndrome including obesity, insulin resistance, hyperglycemia, 
hyperlipidemia, and hepatic steatosis (1), however, there is an emerging concept that abberant gut  
 
 
 
  
 
microbiota may be involved in the pathogenesis of obesity and its related metabolic 
abnormalities.  The human microbiome consists of trillions of microorganisms, most of which 
reside in the gastrointestinal tract. These microbiota are essential for normal physiological 
functioning,  However, when disrupted, alterations in the microbiome may underlie the host’s 
susceptibility to illness, and low grade systemic inflammation.  We previously published results 
showing CDD, which is of known composition, alters gut microbiota composition, inducing low 
grade inflammation and the development of metabolic syndrome as a result of macronutrient 
deficiencies, such as soluble fiber, needed for adequate innate immune function. The soluble 
Fiber inulin is a naturally occurring fructan that isn’t digested in the upper gastrointestinal tract, 
but rather degraded in the colon by indigenous bacteria, stimulating the growth of beneficial 
bacteria, particularly  bifidobacteria, which has been shown to improve host health (2–5). 
Moreover, microbial fermentation of inulin produces SCFA, acetate, butyrate and propionate, 
which promotes a healthy microbiota by decreasing luminal pH as well as inhibiting the growth 
and activity of pathogenic bacteria  (6-7).We proposed that  CDD causes a reduced intestinal 
epithelial cell proliferation resulting in impaired host defense mechanisms and increased bacterial 
product translocation which drives low grade inflammation and that soluble fiber can protect 
from the consequences of CDD therein.. In this study, we aimed to determine the extent to which 
CDD and fiber supplementation impacts “classic” gut inflammation such as IBD.  
Several animal models have provided insight to the pathology of IBD. DSS-induced 
colitis is one of the most used models in which rodents receiving DSS in their drinking water 
develop acute and chronic colitis resembling ulcerative colitis in human patients (8). Although 
 
 
 
 
  
 
the mechanism by which DSS induces colitis remains to be elucidated, it has been widely 
accepted that DSS damages the mucosal barrier exposing intestinal epithelial cells to luminal 
antigens eliciting a robust inflammatory response (7–10).  
Here we report that CDD exacerbates DSS induced colitis and supplementation with 
soluble fiber inulin cause severe adverse effects such as a completely destroyed intestinal 
epithelium and that fiber supplementation may not be an effective therapeutic treatment for those 
suffering from IBD. 
 
 
3.3 Materials and Methods 
 
 
3.3.1 Animals 
 
 
 Four week old male Wild-type C57BL/6  and Il10−/− mice were purchased from Jackson 
Laboratories. All mice were then housed at Georgia State University, Atlanta, Georgia, USA 
under institutionally-approved protocols (Institutional Animal Care and Use Committee no. 
A14033). Mice were fed Purina rodent chow no. 5001, which is commonly used in many vivaria 
from LabDiets, unless other diet is specified. 
 
 
  
3.3.2 Diets 
 
 
Diets were formulated and procured from Research Diets Inc, New Brunswick, NJ.  
The composition of all diets as previously described were used in this study.  Fiber was 
added on a similar per kcal basis in low (10%) and high (60%) fat formulas, and inulin was 
considered as1.0 kcal/g replacing an equal amount of kcals from starch (or maltodextrin in 
formulas with 60% kcal fat).  We considered cellulose to provide no calories. 
 
 
3.3.3 DSS Induced Acute-colitis 
 
 
Animals were fed with either low or high fat diet supplemented with high cellulose or 
inulin fiber 7 days prior and during acute colitis induced by DSS.  Mice received 2.5% DSS 
(W/V) (36,000-50,000kDa; MP Biomedicals, Solon, OH, USA) in drinking water ad libitum for 
7 days continuously for induction of acute colitis (5 mice per group). Control mice were given 
water only. During this period, mice were weighed and feces were collected every day and 
frozen at −20°C for fecal Lcn-2 analysis. After 7 days, mice were bled via retroorbital plexus 
and hemolysis-free serum was collected by centrifugation using serum separator tubes (BD 
Biosciences, Franklin Lakes, NJ). Mice were sacrificed by CO2 euthanasia. Spleen and colon 
weights and lengths were measured. A small piece (50 mg) of proximal colon was taken for 
MPO analysis and RNA extraction, and the rest of the colon fixed in 10% buffered formalin for 
histological studies.
  
 
3.3.4 Haematoxylin and eosin staining and histopathologic analysis 
 
 
Following euthanasia, mouse colons and small intestines were fixed in 10% buffered 
formalin for 24 h at room temperature and then embedded in paraffin. Tissues were sectioned at 
5 μm thickness and stained with haematoxylin and eosin (H&E) using standard protocols. H&E- 
stained slides were scored as follows. Each colon was assigned four scores based on the degree 
of epithelial damage and inflammatory infiltrate in the mucosa, submucosa and 
muscularis/serosa, as previously described. 
 
3.3.5 Quantification of faecal LCN2 by ELISA 
 
 
   For quantification of faecal LCN2 by ELISA, frozen faecal samples were reconstituted 
in PBS containing 0.1% Tween 20 to a final concentration of 100 mg ml
−1 
and vortexed for 20 
min to produce a homogenous faecal suspension. These samples were then centrifuged for 10 
min at 14,000g and 4 °C. Clear supernatants were collected and stored at −20 °C until analysis. 
LCN2 levels were estimated in the supernatants using Duoset murine LCN2 ELISA kit (R&D 
Systems, Minneapolis, Minnesota) using the colourimetric peroxidase substrate 
tetramethylbenzidine, and optical density was read at 450 nm (Versamax microplate reader). 
For determination of colitis incidence, a faecal LCN2 level ≥ 500 ng per g of faeces was used to 
determine colitic mice. 
 
 
3.3.6 Statistical analysis 
 
 
Results are expressed as ± SEM analyzed using GraphPad Prism Software, version 6.01. 
Significance was determined using Student’s t test and one-way ANOVA corrected for multiple 
comparisons with a Bonferroni test.  Differences were noted as significant at *P≤0.05. 
 
 
 
 
 
3.4 Results 
 
 
3.4.1 Soluble fiber supplemented purified diet attenuates colitis in susceptible mice.. 
Initial experiments evaluated the effects of CDD and fiber supplementation in Il10
−/− 
mice.  The hallmark of acute colitis is the presence of immune cell infiltration corresponding to 
changes in gross colon and ceacum morphology.  Addition of soluble fiber reduced the extent 
and incidence of colitis in Il10
−/− 
mice (Fig. 1a-d).  Faecal lipocalin 2 (LCN2) is a sensitive and 
broadly dynamic marker of intestinal inflammation in mice (11) Soluble fiber treated Il10−/− mice 
exhibited decreased faecal LCN2 levels 22 days after initial exposure (Fig. 1e).  Thus, CDD does 
not increase severity of colitis in susceptible host and supplementation with soluble fiber inulin 
likely has a modest protective effect against colitis. 
 
3.4.2 Soluble fiber inulin does not protect against DSS challenge in purified diet-fed mice. 
 
The previous results showed that in a susceptible host, CDD supplementation with soluble 
fiber inulin provided moderate protection. We next wanted to investigate the impact of CDD 
supplemented with soluble fiber in a model of acute colitis induced by DSS. We hypothezised 
that CDD exacerbation of DSS induced colitis could be prevented by soluble fiber. Unlike 
previous work where inulin could prevent intestinal shortening and diet induced adiposity, when 
mice were challenged with DSS during treatment with CDD supplementation, inulin caused 
severe adverse effects (Fig 2. a-f). Mice pretreated with inulin supplementation showed 
protection against colonic shortening and decreased ceacum weights.  This protection was 
abolished after 3 days of DSS administration, as inulin contributed to colonic tissue damage, as 
seen in histopathological changes,  rectal bleeding and decreased feacal LCN2  
levels  (Fig. 3 a-e). 
  
 
 
 
3.4.4 Soluble fiber inulin does not protect against DSS challenge in high fat diet-fed mice. 
 
To further elucidate the impact by which CDD supplementation exacerbates DSS-induced 
colitis, we administered high-fat diet  (60% kcal/fat) supplemented with inulin.  Similar to CDD, 
HFD supplementation against DSS challenge resulted in severe rectal bleeding, weight loss, 
dramatic loss of colon pathology and even death (Fig 4. a-f). 
 
 
3.5 Discussion 
 
In the present study, CDD supplementation with soluble fiber did not protect against 
subsequent induction of colitis by DSS challenge.  Contrary to our hypothesis, soluble fiber 
inulin tended to aggravate the inflammation causing the mice on CDD inulin supplementation to 
get very sick reaching close to their end point.  Based on results from our previous studies, we 
expected CDD inulin supplementation to protect against DSS phenotype.  This lack of 
protection might be due to the fact that although inulin is promoting intestinal growth, its also 
promoting bacterial growth which in turns cause increased LPS levels resulting in a more severe 
inflammatory response.  Supplementing chow with inulin was not able to correct the DSS 
phenotype, however, it did appear to protect on a basal level.  Overall, this data suggest that 
supplementing diet with inulin can correct mild inflammation, when there is a more severe 
challenge, as with DSS,  there could be detrimental effects and even death. 
 The past few decades have witnessed a dramatic increase in low grade systemic 
disorders such as obesity and metabolic syndrome due to, in part, the mass production of energy  
 
 
 
 
  
 
dense foods lacking complex fibers and carbohydrates.  As several studies, including our 
previous work, have shown that diet influences microbiota composition in a way that promotes 
and predisposes to a myriad of metabolic disorders and development of IBD.  The severe acute 
consequences of diet induced intestinal inflammation warrant understanding in the mechanisms 
involved which could lead to novel theraperies 
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Figure 3.1 Soluble fiber supplemented purified diet attenuates colitis in susceptible mice. Il10−/− mice were maintained on the 
specified diet for 12 weeks. A. Colon weight B. Colon length. C. Ceacum weight. D. Spleen weight. E. Feacal levels of the 
inflammatory marker LCN2 over time.  Data are represented as mean ± SEM of N=5 mice per group. Significance was determined 
by Student t test. *P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Soluble fiber inulin does not protect against DSS challenge in purified diet-fed mice. C57bl/6 mice were 
maintained on the specified diet for 2 weeks and at the start of the second week exposed to drinking water containing 2.5% DSS for 
1 week. A. Body weight over time. B. Fat pad weight. C. Spleen weight. D. Colon weight. E. Colon length. F. Ceacum weight. 
Data are represented as mean ± SEM of N=5 mice per group. Significance was determined by Student t test. *P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Soluble fiber inulin worsens intestinal inflammation in DSS treated mice under purified diet. C57bl/6 mice were maintained 
on the specified diet for 2 weeks and at the start of the second week exposed to drinking water containing 2.5% DSS for 1 week. A. 
Representative paraffin sections of colonic tissues stained with H&E. B. % Rectal bleeding after DSS-induced acute colitis. C-E. Feacal 
levels of the inflammatory marker LCN2 over time. 
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Figure 3.4 Soluble fiber inulin does not protect against DSS challenge in high fat diet-fed mice. C57bl/6 mice were maintained 
on the specified diet for 3 weeks and at the start of the third week exposed to drinking water containing 2.5% DSS for 1 week. A. 
Body weight over time. B. Fat pad weight. C. Spleen weight. D. Colon weight. E. Colon length. F. Ceacum weight.  Data are 
represented as mean ± SEM of N=4 mice per group. Significance was determined by Student 
t test. *P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Soluble fiber inulin dampened basal intestinal inflammation but do not protect against DSS challenge. C57bl/6 
mice were maintained on the specified diet for 2 weeks and at the start of the second week exposed to drinking water 
containing 2.5% DSS for 1 week. A. Body weight over time. B. Colon weight. C. Colon length. D. Ceacum weight.  E-F. 
Feacal levels of the inflammatory marker LCN2 over time.  Data are represented as mean ± SEM of N=5 mice per group. 
Significance was determined by Student t test. *P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
